| 4.77 -0.1 (-2.05%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.85 |
1-year : | 6.62 |
| Resists | First : | 5 |
Second : | 5.67 |
| Pivot price | 4.79 |
|||
| Supports | First : | 3.94 |
Second : | 3.27 |
| MAs | MA(5) : | 4.9 |
MA(20) : | 4.9  |
| MA(100) : | 6.13 |
MA(250) : | 14.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.2 |
D(3) : | 46.8 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 26.83 | Low : | 3.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JSPR ] has closed above bottom band by 46.9%. Bollinger Bands are 80.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 79 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.91 - 4.93 | 4.93 - 4.95 |
| Low: | 4.67 - 4.69 | 4.69 - 4.72 |
| Close: | 4.73 - 4.77 | 4.77 - 4.81 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Wed, 21 May 2025
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey
Thu, 15 May 2025
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Wed, 14 May 2025
Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Wed, 14 May 2025
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
Wed, 14 May 2025
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
Mon, 12 May 2025
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 105 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 1,670 (K) |
| EPS | -4.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -54.6 % |
| Return on Equity (ttm) | -101.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|